Valeritas brings in $50.6mm via private placement
Executive Summary
BioValve Technologies's Valeritas (insulin drug delivery systems) brought in $50.6mm, which includes $19.9mm in convertible debt, through a financing of both Series A and B preferred shares and warrants to Abingworth Management, MPM Capital, Pitango Venture Capital, and US Venture. Valeritas could raise up to $87mm in the round.
Deal Industry
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
- Transdermal
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice